NCT05709899 is a NA clinical trial of nerve blocks in Colo-rectal Cancer, sponsored by Assiut University.

Who is sponsoring NCT05709899?

NCT05709899 is sponsored by Assiut University.

What drugs are being tested in NCT05709899?

Interventions in NCT05709899: nerve blocks.

What condition does NCT05709899 study?

NCT05709899 studies Colo-rectal Cancer.

Is NCT05709899 still recruiting?

NCT05709899 is currently status unknown. Last updated 27 June 2023.

Last reviewed 2023-06-27 · How we verify

NCT05709899

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison of Ultrasound-guided Erector Spinae Plane Block and Transmuscular Quadratus Lumborum Block

Status unknown NA Last updated 27 June 2023

What this trial tests

NA trial testing nerve blocks in Colo-rectal Cancer in 44 participants. Status unknown.

Timeline

30 August 2023

Primary endpoint
30 November 2025

31 December 2025

Quick facts

Lead sponsor	Assiut University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	44
Start date	30 August 2023
Primary completion	30 November 2025
Estimated completion	31 December 2025

Drugs / interventions tested

nerve blocks

Conditions studied

Colo-rectal Cancer — all drugs for Colo-rectal Cancer →

Sponsor

Assiut University

Who can join

Adults 18 to 70, any sex, with Colo-rectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to compare the postoperative analgesic effect of bupivacaine injection via ultrasound-guided erector spinae block versus transmuscular quadratus lumborum block in patients undergoing abdominal cancer surgery

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Colo-rectal Cancer

Currently open trials in the same condition.

NCT06645015 — The AIDPRO-CRC Trial · NA · recruiting
NCT07145255 — Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07085169 — Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC · Phase 2 · recruiting
NCT06880055 — Shield Post-Approval Study Protocol · recruiting
NCT06905925 — The Effect of the Training Program Given to Permanent Colostomy Patients on Self-efficacy · NA · recruiting

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05709899 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 27 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05709899.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing